Advanced search
Publication Cover
Acta Cardiologica Volume 78, 2023 - Issue 3
Submit an article Journal homepage
233
Views
4
CrossRef citations to date
0
Altmetric
Original Scientific Papers

Prevalence and predictors of left atrial thrombosis in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants

Filippo AngeliniDivision of Cardiology, Cardiovascular and Thoracic Department of Medical Sciences, University of Turin and ‘Città della Salute e della Scienza’ Hospital, Turin, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4711-0891
ORCID Icon,
Pier Paolo BocchinoDivision of Cardiology, Cardiovascular and Thoracic Department of Medical Sciences, University of Turin and ‘Città della Salute e della Scienza’ Hospital, Turin, Italy
,
Mattia PeyracchiaDivision of Cardiology, Cardiovascular and Thoracic Department of Medical Sciences, University of Turin and ‘Città della Salute e della Scienza’ Hospital, Turin, Italy
,
Andrea SagliettoDivision of Cardiology, Cardiovascular and Thoracic Department of Medical Sciences, University of Turin and ‘Città della Salute e della Scienza’ Hospital, Turin, Italy
,
Massimo MagnanoDivision of Cardiology, Cardiovascular and Thoracic Department of Medical Sciences, University of Turin and ‘Città della Salute e della Scienza’ Hospital, Turin, ItalyORCID Iconhttps://orcid.org/0000-0002-3531-104X
ORCID Icon,
Nicolò PatanèDivision of Cardiology, Cardiovascular and Thoracic Department of Medical Sciences, University of Turin and ‘Città della Salute e della Scienza’ Hospital, Turin, Italy
,
Fabrizio D’AscenzoDivision of Cardiology, Cardiovascular and Thoracic Department of Medical Sciences, University of Turin and ‘Città della Salute e della Scienza’ Hospital, Turin, Italy
,
Carla GiustettoDivision of Cardiology, Cardiovascular and Thoracic Department of Medical Sciences, University of Turin and ‘Città della Salute e della Scienza’ Hospital, Turin, Italy
,
Matteo AnselminoDivision of Cardiology, Cardiovascular and Thoracic Department of Medical Sciences, University of Turin and ‘Città della Salute e della Scienza’ Hospital, Turin, ItalyORCID Iconhttps://orcid.org/0000-0002-6311-4270
ORCID Icon,
Fiorenzo GaitaDivision of Cardiology, Cardiovascular and Thoracic Department of Medical Sciences, University of Turin and ‘Città della Salute e della Scienza’ Hospital, Turin, Italy
&
Elisabetta TosoDivision of Cardiology, Cardiovascular and Thoracic Department of Medical Sciences, University of Turin and ‘Città della Salute e della Scienza’ Hospital, Turin, Italy
 show all
Pages 290-297 | Received 24 Jun 2021, Accepted 06 Nov 2021, Published online: 25 Nov 2021

References

  • Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the US adult population. Am J Cardiol. 2013;112(8):1142–1147.
  • Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European union, from 2000 to 2060. Eur Heart J. 2013;34(35):2746–2751.
  • Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857.
  • Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.
  • Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;42:373–498.
  • Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010;303(4):333–340.
  • Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and Meta-analyses. Circ Arrhythm Electrophysiol. 2009;2(4):349–361.
  • Airaksinen KE, Gronberg T, Nuotio I, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (finnish CardioVersion) study. J Am Coll Cardiol. 2013;62(13):1187–1192.
  • Arnold AZ, Mick MJ, Mazurek RP, et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol. 1992;19(4):851–855.
  • Lee WC, Fang CY, Chen YL, et al. Left atrial or left atrial appendage thrombus resolution after adjustment of oral anticoagulant treatment. J Stroke Cerebrovasc Dis. 2019;28(1):90–96.
  • Bertaglia E, Anselmino M, Zorzi A, et al. NOACs and atrial fibrillation: incidence and predictors of left atrial thrombus in the real world. Int J Cardiol. 2017;249:179–183.
  • Harada M, Koshikawa M, Motoike Y, et al. Left atrial appendage thrombus prior to atrial fibrillation ablation in the era of direct oral anticoagulants. Circ J. 2018;82(11):2715–2721.
  • Cappato R, Ezekowitz MD, Klein AL, et al. X-VeRT investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346–3355.
  • Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272.
  • Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey. Chest. 2010;138(5):1093–1100.
  • Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2015;28(1):1–39.e14.
  • Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol. 1994;23(4):961–969.
  • Bocchino PP, Angelini F, Toso E. Atrial fibrillation and coronary artery disease: a review on the optimal use of oral anticoagulants. Rev Cardiovasc Med. 2021;22(3):635–648.
  • Albertsen IE, Rasmussen LH, Overvad TF, et al. Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and Meta-analysis. Stroke. 2013;44(5):1329–1336.
  • Frenkel D, D’Amato SA, Al-Kazaz M, et al. Prevalence of left atrial thrombus detection by transesophageal echocardiography: a comparison of continuous non-vitamin K antagonist oral anticoagulant versus warfarin therapy in patients undergoing catheter ablation for atrial fibrillation. JACC Clin Electrophysiol. 2016;2(3):295–303.
  • Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016;388(10055):1995–2003.
  • Paciaroni M, Agnelli G, Caso V, et al. Causes and risk factors of cerebral ischemic events in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants for stroke prevention. Stroke. 2019;50(8):2168–2174.
  • Blokhin IO, Lentz SR. Mechanisms of thrombosis in obesity. Curr Opin Hematol. 2013;20(5):437–444.
  • Overvad TF, Rasmussen LH, Skjøth F, et al. Body mass index and adverse events in patients with incident atrial fibrillation. Am J Med. 2013;126(7):640.e9-640–640.e17. e6.4E17.
  • Steffel J, Verhamme P, Potpara TS, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393.
  • Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009;373(9658):155–166.
  • Ayirala S, Kumar S, O’Sullivan DM, et al. Echocardiographic predictors of left atrial appendage thrombus formation. J Am Soc Echocardiogr. 2011;24(5):499–505.
  • Rocca B, Fox KAA, Ajjan RA, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC working group on thrombosis. Eur Heart J. 2018;39(19):1672–1686f.
  • Gosselin RC, Francart SJ, Hawes EM, et al. Heparin-Calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level? Ann Pharmacother. 2015;49(7):777–783.
  • Katsanos AH, Bhole R, Frogoudaki A, et al. The value of transesophageal echocardiography for embolic strokes of undetermined source. Neurology. 2016;87(10):988–995.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.